Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Medivir AB ( (SE:MVIR) ).
Medivir has established a Scientific Expert Council comprising world-leading specialists in Osteogenesis Imperfecta as it accelerates development of its orphan-designated drug candidate MIV-711 for this rare bone disorder. The council will advise on study design and execution for an upcoming clinical proof-of-concept trial, aiming to position Medivir in a potential market of at least USD 2.5 billion while addressing a major unmet need for disease-modifying OI therapies.
The council members, drawn from leading European centers in metabolic and rare bone diseases, bring deep clinical and research expertise in OI and related skeletal disorders. Their involvement underscores the strategic importance of MIV-711, which targets cathepsin K to potentially improve bone strength and reduce fracture rates, and may enhance Medivir’s credibility and execution capacity in a complex rare-disease indication.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a Stockholm-listed pharmaceutical company focused on developing innovative treatments for diseases with high unmet medical need. Its pipeline includes the cathepsin K inhibitor MIV-711, now being advanced for Osteogenesis Imperfecta, and fostrox for primary liver cancer, targeting sizable rare disease and oncology markets.
Average Trading Volume: 9,854,531
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.24B
Find detailed analytics on MVIR stock on TipRanks’ Stock Analysis page.